Sanofi Terminates Collaboration with Sangamo for Sickle Cell Disease Program

Seeking Alpha2022-01-06

Sangamo Therapeutics(NASDAQ:SGMO)falls 8% premarket following an announcement that Sanofi(NASDAQ:SNY)will be transitioning its rights and obligations related to SAR445136, a zinc finger nuclease gene-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

huathuatking
2022-01-06
huathuatking
Ok
PauT
2022-01-06
PauT
👍
JiaocyTi
2022-01-06
JiaocyTi
6606
SYFU
2022-01-06
SYFU
Ish the oh
Gladys80
2022-01-06
Gladys80
👍
Gladys80
2022-01-06
Gladys80
👍

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127463793?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-06 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127463793","market":"us","top_or_hot":-1,"title":"Sanofi Terminates Collaboration with Sangamo for Sickle Cell Disease Program","media":"Seeking Alpha","content":"<div>\n<p>Sangamo Therapeutics(NASDAQ:SGMO)falls 8% premarket following an announcement that Sanofi(NASDAQ:SNY)will be transitioning its rights and obligations related to SAR445136, a zinc finger nuclease gene-...</p>\n\n<a href=\"https://seekingalpha.com/news/3785825-sanofi-terminates-collaboration-with-sangamo-for-sickle-cell-disease-program\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Terminates Collaboration with Sangamo for Sickle Cell Disease Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Terminates Collaboration with Sangamo for Sickle Cell Disease Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3785825-sanofi-terminates-collaboration-with-sangamo-for-sickle-cell-disease-program><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sangamo Therapeutics(NASDAQ:SGMO)falls 8% premarket following an announcement that Sanofi(NASDAQ:SNY)will be transitioning its rights and obligations related to SAR445136, a zinc finger nuclease gene-...</p>\n\n<a href=\"https://seekingalpha.com/news/3785825-sanofi-terminates-collaboration-with-sangamo-for-sickle-cell-disease-program\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMO","symbol_name":"Sangamo Therapeutics Inc","start_time":0,"source_url":"https://seekingalpha.com/news/3785825-sanofi-terminates-collaboration-with-sangamo-for-sickle-cell-disease-program","article_id":"1127463793","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127463793","pubTimestamp":1641477931,"sourceInfo":null,"weMediaInfo":null,"summary":"Sangamo Therapeutics(NASDAQ:SGMO)falls 8% premarket following an announcement that Sanofi(NASDAQ:SNY","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGMO":"Sangamo Therapeutics Inc","GCVRZ":"Sanofi"},"translate_title":"赛诺菲终止与Sangamo的镰状细胞疾病项目合作","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GCVRZ":0.9,"SGMO":0.9},"content_text":"Sangamo Therapeutics(NASDAQ:SGMO)falls 8% premarket following an announcement that Sanofi(NASDAQ:SNY)will be transitioning its rights and obligations related to SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development by both the companies for the treatment of sickle cell disease (SCD), back to Sangamo over H1 2022.The Companies are collaborating on an orderly transition, while Sangamo explores options to advance the program, including seeking a new collaboration partner.Sanofi has elected to transition the SCD program to Sangamo following a recent change in Sanofi’s cell therapy strategy to focus on universal genomic medicine approaches.SGMO anticipates the Phase 1/2 PRECIZN-1 study of SAR445136 to be completed as planned.Sangamo expects that Sanofi will continue to pay the costs of the PRECIZN-1 study until the termination date of June 28, 2022, as contemplated by the Collaboration Agreement.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9008533016,"gmtCreate":1641480153783,"gmtModify":1676533619446,"author":{"id":"3572923710314905","authorId":"3572923710314905","authorIdStr":"3572923710314905","name":"huathuatking","avatar":"https://static.tigerbbs.com/2f213995240eaab2cd1ce03e0a2cde28","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572923710314905"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008533016","repostId":1127463793,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008530755,"gmtCreate":1641480085999,"gmtModify":1676533619414,"author":{"id":"4091365317251540","authorId":"4091365317251540","authorIdStr":"4091365317251540","name":"PauT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4091365317251540"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008530755","repostId":1127463793,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008530562,"gmtCreate":1641480060353,"gmtModify":1676533619414,"author":{"id":"3581742924827239","authorId":"3581742924827239","authorIdStr":"3581742924827239","name":"JiaocyTi","avatar":"https://static.tigerbbs.com/c16d760078e396b46033bc97afede0c8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581742924827239"},"htmlText":"6606","listText":"6606","text":"6606","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008530562","repostId":1127463793,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008504174,"gmtCreate":1641478187850,"gmtModify":1676533619045,"author":{"id":"3574550472976902","authorId":"3574550472976902","authorIdStr":"3574550472976902","name":"SYFU","avatar":"https://static.tigerbbs.com/7e9e3d2d44a5d4d299cb39a2cdbcbae1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3574550472976902"},"htmlText":"Ish the oh&nbsp;","listText":"Ish the oh&nbsp;","text":"Ish the oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008504174","repostId":1127463793,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008505291,"gmtCreate":1641478093220,"gmtModify":1676533619034,"author":{"id":"4087907126409640","authorId":"4087907126409640","authorIdStr":"4087907126409640","name":"Gladys80","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087907126409640"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008505291","repostId":1127463793,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008505666,"gmtCreate":1641478064347,"gmtModify":1676533619033,"author":{"id":"4087907126409640","authorId":"4087907126409640","authorIdStr":"4087907126409640","name":"Gladys80","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087907126409640"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008505666","repostId":1127463793,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":75,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127463793"}